Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Adrenocortical carcinoma is a rare but aggressive cancer with unknown aetiology. Constitutive activation of beta-catenin is the most frequent alteration in benign and malignant adrenocortical tumours in patients. Here, we show that constitutive activation of beta-catenin in the adrenal cortex of transgenic mice resulted in progressive steroidogenic and undifferentiated spindle-shaped cells hyperplasia as well as dysplasia of the cortex and medulla. Over a 17 months time course, transgenic adrenals developed malignant characteristics such as uncontrolled neovascularization and loco-regional metastatic invasion. These oncogenic events were accompanied by ectopic differentiation of glomerulosa at the expense of fasciculata cells, which caused primary hyperaldosteronism. Altogether these observations demonstrate that constitutively active beta-catenin is an adrenal oncogene which triggers benign aldosterone-secreting tumour development and promotes malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Familial adenomatous polyposis
Galiatsatos, P., & Foulkes, W. D. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00375.x · Cited by 757 · cited 1×
“[20], or mutations of the third exon of CTNNB1 (β-catenin gene) which encodes the amino-”
BackgroundErk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin
Ding, Q., Xia, W., Liu, J.-C., Yang, J.-Y., Lee, D.-F., Xia, J., Bartholomeusz, G., Li, Y., Pan, Y., Li, Z., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.009 · Cited by 597 · cited 1×
“IGF2 is a good candidate as a secondary factor involved in malignant progression: it is almost invariably overexpressed in adrenal carcinomas [6-9] and reciprocal interactions between IGF signalling and β-catenin have been described in different cellular systems [41-44].”
BackgroundApc Tumor Suppressor Gene Is the “Zonation-Keeper” of Mouse Liver
Benhamouche, S., Decaens, T., Godard, C., Chambrey, R., Rickman, D. S., Moinard, C., Vasseur-Cognet, M., Kuo, C. J., Kahn, A., Perret, C., et al. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.03.015 · Cited by 543 · cited 1×
“through β-catenin inhibition [60].”
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.
Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., & Donehower, L. A. (1993) · Nature Genetics · doi:10.1038/ng1193-225 · Cited by 542
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474
Self-citationDistinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis
Giordano, T. J., Thomas, D. G., Kuick, R., Lizyness, M., Misek, D. E., Smith, A. L., Sanders, D., Aljundi, R. T., Gauger, P. G., Thompson, N. W., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63846-1 · Cited by 383
A two-step model for colon adenoma initiation and progression caused by APC loss
Phelps, R. A., Chidester, S., Dehghanizadeh, S., Phelps, J., Sandoval, I. T., Rai, K., Broadbent, T., Sarkar, S., Burt, R. W., & Jones, D. A. (2009) · Cell · doi:10.1016/j.cell.2009.02.037 · Cited by 286 · cited 1×
“of APC [40].”
Kim, A. C., Reuter, A. L., Zubair, M., Else, T., Serecky, K., Bingham, N. C., Lavery, G. G., Parker, K. L., & Hammer, G. D. (2008) · Development · doi:10.1242/dev.021493 · Cited by 202 · cited 2×
“development and cell renewal in the adult adrenal cortex [21].”
BackgroundPreclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma
Barlaskar, F. M., Spalding, A. C., Heaton, J. H., Kuick, R., Kim, A. C., Thomas, D. G., Giordano, T. J., Ben-Josef, E., & Hammer, G. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1456 · Cited by 189
Frequent mutations of β‐catenin gene in sporadic secreting adrenocortical adenomas*
Tadjine, M., Lampron, A., Ouadi, L., & Bourdeau, I. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03033.x · Cited by 153
Gaujoux, S., Tissier, F., Groussin, L., Libé, R., Ragazzon, B., Launay, P., Audebourg, A., Dousset, B., Bertagna, X., & Bertherat, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0631 · Cited by 142 · cited 2×
“These mutations were found in benign and malignant tumours as well as in H295R cells, derived from a human ACC [22-25].”
BackgroundSelf-citationSeccia, T. M., Fassina, A., Nussdorfer, G. G., Pessina, A. C., & Rossi, G. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00867 · Cited by 131
Detection of somatic β-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD)
Tadjine, M., Lampron, A., Ouadi, L., Horvath, A., Stratakis, C. A., & Bourdeau, I. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03273.x · Cited by 108
Cited by
Wnt/beta-catenin pathway: modulating anticancer immune response
Pai, S. G., Carneiro, B. A., Mota, J. M., Costa, R., Leite, C. A., Barroso-Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 703
Update in Adrenocortical Carcinoma
Fassnacht, M., Kroiss, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Vaidya, A., Mulatero, P., Baudrand, R., & Adler, G. K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00139 · Cited by 299
MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans
Hughes, C. R., Guasti, L., Meimaridou, E., Chuang, C.-H., Schimenti, J. C., King, P. J., Costigan, C., Clark, A. J. L., & Metherell, L. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60224 · Cited by 260
Metadata
- Authors
- Berthon, A., Sahut-Barnola, I., Lambert-Langlais, S., de Joussineau, C., Damon-Soubeyrand, C., Louiset, E., Taketo, M. M., Tissier, F., Bertherat, J., Lefrançois-Martinez, A.-M., Martinez, A., & Val, P.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-01-27
- Volume
- 19
- Issue
- 8
- Pages
- 1561-1576
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2141197851
- Cited by
- 239
- References
- 18
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.